Filter By
Clear all Advanced
I am/have/had
added new label for I am/have/had
more
I am looking for
added new label for I am looking for
more
Advanced Filters
Found 46 clinical trials
Role of Lymphnode Dissection in Men With Prostate Cancer Treated With Radical Prostatectomy

This is particularly of interest considering the rapidly advancing technical possibilities, both in imaging and in the treatment of prostate cancer, since this enables an earlier and more individual intervention in the case of recurrence.

cancer
metastasis
endocrine therapy
immunological adjuvant
adjuvant
  • 0 views
  • 19 Feb, 2024
Study of Cabozantinib in Combination With Atezolizumab Versus Second NHT in Subjects With mCRPC

This is a Phase 3, multi-center, randomized, open-label, controlled study designed to evaluate the safety and efficacy of cabozantinib given in combination with atezolizumab versus a second novel hormonal therapy (NHT) in men with metastatic castration-resistant prostate cancer (mCRPC) who have previously been treated with one, and only one, NHT …

darolutamide
adenocarcinoma of prostate
metastatic hormone refractory prostate cancer
metastatic prostate cancer
serum testosterone
  • 0 views
  • 19 Feb, 2024
Multicenter Study of Hypofractionated Postoperative Radiotherapy in Patients Diagnosed With Prostate Carcinoma

The objective of this study is to evaluate, in patients diagnosed with prostate cancer who undergo radical prostatectomy and who require postoperative radiotherapy, tolerance in terms of acute and chronic GU and GI toxicity and efficacy in terms of biochemical control and survival, as well as of quality of life, …

prostate carcinoma
adenocarcinoma of prostate
lymph node disease
bone scan
immunological adjuvant
  • 0 views
  • 19 Feb, 2024
PRO-MERIT (Prostate Cancer Messenger RNA Immunotherapy)

Open-label, multicenter, dose titration and expansion three-arm trial to evaluate the safety, tolerability, immunogenicity, and preliminary efficacy of W_pro1 cancer vaccine (W_pro1) in patients with metastatic castration resistant prostate cancer (mCRPC) W_pro1 in combination with goserelin acetate with or without cemiplimab, in patients with high-risk, localized prostate cancer (LPC)

gonadotrophin
bladder cancer
antibiotics
gonadorelin
squamous cell carcinoma of the skin
  • 2 views
  • 19 Feb, 2024
Interactive Decision Aid for Men Diagnosed With Prostate Cancer

Prostate cancer is the second leading cause of cancer related deaths in the western world (National Cancer Institute, 2011). Prostate cancer diagnosis relates to significant psychological distress (Roesch et al, 2005; Hervouet et al, 2005).

cancer diagnosis
  • 0 views
  • 19 Feb, 2024
Molecular Imaging of Prostate Cancer Using Radiofluorinated PSMA Ligand

Eligible patients have prostate cancer that was treated with surgery or radiation therapy for localized disease and there is evidence of biochemical recurrence and/or metastases on conventional imaging.The objective of this study is to assess the performance in detection of prostate cancer of a new positron emission tomography (PET) radiotracer …

positron emission tomography
molecular imaging
metastasis
pet/mri
MRI
  • 0 views
  • 19 Feb, 2024
EMPOWER Men to Reduce Weight and Inhibit Prostate Cancer Progression

This study will evaluate whether a lifestyle intervention focused on weight loss, EMPOWER, reduces prostate cancer progression at 12 months among men with biochemical recurrence following local treatment for prostate cancer. Half of the men will be randomized to receive the EMPOWER intervention, while the other half will receive standard …

adenocarcinoma of prostate
serum testosterone
definitive treatment
definitive therapy
bone scan
  • 0 views
  • 19 Feb, 2024
18F-PSMA-1007 PET Imaging to Detect Primary Prostate Cancer

To study the added value of 18F-PSMA-1007 PET to mpMRI in the detection of local prostate cancer lesions.

digital rectal examination
positron emission tomography
pet/ct scan
multiparametric magnetic resonance imaging
  • 0 views
  • 19 Feb, 2024
Postop Hypofractionated Radiation Therapy and LHRH in Patients With Prostate Cancer

Prostate cancer is the second most common cancer among Canadian men of which approximately 20-30% present with high-risk tumour characteristic.

adenocarcinoma of prostate
eligard
bone metastases
bone scan
gonadotrophin
  • 0 views
  • 19 Feb, 2024
Adenosine Receptor Antagonist Combination Therapy for Metastatic Castrate Resistant Prostate Cancer

This is a Phase 1b/2, open-label, multicenter platform trial to evaluate the antitumor activity and safety of AB928-based combination therapy in participants with metastatic castrate resistant prostate cancer (mCRPC).

measurable disease
prostatic neoplasms, castration-resistant
cancer
combined modality therapy
testosterone
  • 0 views
  • 19 Feb, 2024